ACORI Summit

ACORI-Summit-3333x666

 

Activating Equity in Community Oncology Research

The Association of Community Cancer Centers (ACCC) has established the ACCC Community Oncology Research Institute (ACORI) to build on its existing mission to close the gap in cancer research through optimal oncology partnerships. As part of this mission, ACCC hosted the ACORI Call to Action Summit, a two-day virtual event that explored practical solutions to strengthen and diversify oncology clinical trials in communities across the country.

The Summit's interactive discussions focused around:

  • The importance of expanding access to clinical trials for patients of all background—to ensure the highest quality care
  • Strategies for engaging patients and their caregivers in shared decision-making around trial enrollment
  • Case studies to demonstrate solutions for optimizing accrual and overcoming barriers to trial participation
  • Tools and resources to support care teams, including budget forms, IRB templates, etc.
  • How to incorporate the patient perspective into trial design: insights for trial sponsors   

We look forward to continuing these conversations and taking action that will tie directly into ACORI's three domains of equity, capacity building, and research diffusion. If you were not able to join us live, the ACORI Summit is now available to view on-demand

If you have any additional ideas or feedback, please reach out directly to  Victoria Zwicker, MPH, Program Manager, Provider Education.

Executive Summary

ACORI Executive SummaryThe ACORI Call to Action Summit’s Executive Summary was developed as an overview of the action items co-developed by the Summit participants for ACCC and oncology programs and practices, as well as other stakeholders. These action items are intended to serve as foundational resources in support of the ACORI stakeholders in their work to improve equity and inclusion in research and diversify clinical trials.

Learn more about the Summit, the developed action items, and more in this comprehensive Executive Summary.
Download Now

 

12:00 PM EDT
Welcoming Remarks

12:55 PM EDT
Advancing Health Equity through Community Cancer Research

Sybil Green, JD, RPh, MHA, Diversity and Inclusion Officer, ASCO (Moderator)
Karen Winkfield, MD, PhD, Executive Director, Meharry-Vanderbilt Alliance
Ysabel Duron, President/Executive Director, The Latino Cancer Institute
Linda Burhansstipanov, MSPH, DrPH, Founder, Native American Cancer Research Corporation; President, Native American Cancer Initiatives, Incorporated

1:40 PM EDT
Panel Conversation: Centering the Patient Perspective in Community Cancer Research

Jeanne Regnante, Chief Health Equity and Diversity Officer, LUNGevity Foundation (Moderator)
Shonta Chambers, MSW, Executive Vice President, Patient Advocate Foundation
Venus Ginés, MA, P/CHWI, CEO and Founder, Día de la Mujer Latina
Rodney Haring, PhD, MSW, Director, Center for Indigenous Cancer Research, Roswell Park Comprehensive Cancer Center

2:40 PM EDT
Fostering Readiness for Community Cancer Research

Nadine Barrett, PhD, MA, MS, Director, Office of Health Equity and Disparities, Duke Cancer Institute; Director, Duke Community Connections Core, Duke CTSA (Moderator)
Robert Winn, MD, Director and Lipman Chair in Oncology, VCU Massey Cancer Center
Nina Bickell, MD, MPH, Co-Lead, Cancer Prevention and Control, Tisch Cancer Institute
Randall A. Oyer, MD, Medical Director, Ann B. Barshinger Cancer Institute, Penn Medicine Lancaster General Health; ACORI Chair

3:30 PM EDT
Promoting Inclusion of Members of Racial and Ethnic Minority Groups in Cancer Drug Development

Lola A. Fashoyin-Aje, MD, MPH, Deputy Division Director, FDA Oncology Center of Excellence
Jennie R. Crews, MD, MMM, FACP, Medical Director, SCCA Network & Community Sites, Seattle Cancer Care Alliance
Erin Williams MBA, Associate Director, SCCC Clinical Research Operations, University of Texas Southwestern Medical Center, Simmons Comprehensive Cancer Center
Racquel Racadio, MPH, Senior Manager, Diversity and Representation in Clinical Research, Amgen

4:30 PM EDT
Closing Remarks

Randall A. Oyer, MD, Medical Director, Ann B. Barshinger Cancer Institute, Penn Medicine Lancaster General Health; ACORI Chair

 

12:00 PM EDT
Welcoming Remarks

12:30 PM EDT
SU2Cancer-104x60SU2C Special Session

Olajide Williams, MD, Founder and President, Hip Hop Public Health
Sung Poblete, PhD, RN, Chief Executive Officer, SU2C

1:00 PM EDT
Harnessing the Power of Community Partnerships to Improve Patient Accrual

Karen Winkfield, MD, PhD, Executive Director, Meharry-Vanderbilt Alliance

1:15 PM EDT
Breakouts

2:05 PM EDT
Building Research Capacity to Strengthen Cancer Trials in the Community

Lola A. Fashoyin-Aje, MD, MPH, Deputy Division Director, FDA Oncology Center of Excellence

2:20 PM EDT
Breakouts

3:25 PM EDT
Incorporating the Patient Perspective into Trial Design

Carla Strom, MLA, Assistant Director, Operations, Wake Forest Baptist Health Comprehensive Cancer Center

3:40 PM EDT
Breakouts

4:30 PM EDT
Closing Remarks & Call to Action

 

Target Audience

  • Community oncology providers and researcher team members (all disciplines)
  • Patient advocates and advocacy organizations
  • Trial sponsors and industry
  • Research networks and cooperative groups
  • Government and regulatory agencies

From Oncology Issues

Featured Faculty

Fashoyin-Aje-Lola-80x80Lola A. Fashoyin-Aje, MD, MPH
Associate Director, FDA Oncology Center of Excellence

 

Green-Sybil-80x80Sybil Green, JD, RPh, MHA
Diversity and Inclusion Officer, American Society of Clinical Oncology (ASCO)

 

Regnante-Jeanne-80x80Jeanne Regnante
Chief Health Equity and Diversity Officer, LUNGevity Foundation

In Collaboration With

SU2C-200x80

Our Supporters

abbvie-200x80 amgen-200x80 astrazeneca-200x80 eisai-200x80 genentech-200x80 merck-200x80 sanofi-genzyme-200x80-long

This project is supported by AbbVie, Amgen, AstraZeneca, Eisai, Genentech, Merck and Sanofi.

Twitter Highlights

More from #ACORISummit